Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 369
Filter
1.
Hum Reprod Open ; 2021(1): hoaa064, 2021.
Article in English | MEDLINE | ID: mdl-33501384

ABSTRACT

STUDY QUESTION: Is oocyte cryopreservation an applicable option for fertility preservation in unmarried patients with haematological malignancies? SUMMARY ANSWER: Oocyte cryopreservation via the vitrification method is accessible and may be considered an option for fertility preservation in unmarried patients with haematological malignancies. WHAT IS KNOWN ALREADY: Haematological malignancies are most commonly observed amongst adolescent and young adult women. Although the survival rate and life expectancy of those with haematological malignancies have improved, chemotherapy and radiotherapy may impair their reproductive potential. Oocyte cryopreservation is thus an ideal option to preserve their fertility. STUDY DESIGN SIZE DURATION: This study retrospectively evaluated 193 unmarried patients (age: 26.2 ± 0.4 years) with haematological malignancies, who consulted for oocyte cryopreservation across 20 different fertility centres in Japan between February 2007 and January 2015. The primary outcome measures were the oocyte retrievals and oocyte cryopreservation outcomes. The secondary outcome measures were the outcomes following oocyte warming for IVF. PARTICIPANTS/MATERIALS SETTING METHODS: The patients had commenced ovarian stimulation cycles via antagonist, agonist, natural and minimal methods for oocyte retrievals, defined according to the treatment strategy of each respective fertility centre. A vitrification method using the Cryotop safety kit was used for oocyte cryopreservation. ICSIs were used for insemination of warmed oocytes. The endometrial preparation method for embryo transfer was hormonal replacement therapy, except in the case of a patient who underwent a spontaneous ovulatory cycle. MAIN RESULTS AND THE ROLE OF CHANCE: Among 193 patients, acute myeloid leukaemia (n = 45, 23.3%) was most common, followed by acute lymphoid leukaemia (n = 38, 19.7%) and Hodgkin's lymphoma (n = 30, 15.5%). In total, 162 patients (83.9%) underwent oocyte retrieval, and oocytes were successfully cryopreserved for 155 patients (80.3%). The mean number of oocyte retrieval cycles and cryopreserved oocytes were 1.7 ± 0.2 and 6.3 ± 0.4, respectively. As of December 2019, 14 patients (9.2%) had requested oocyte warming for IVF. The survival rate of oocytes after vitrification-warming was 85.2% (75/88). The rates of fertilisation and embryo development were 80.0% (60/75) and 46.7% (28/60), respectively. Ten patients (71.4%) had successful embryo transfers, and seven live births (50.0%) were achieved. LIMITATIONS REASONS FOR CAUTION: This study was limited by its retrospective nature. Additionally, there remains an insufficient number of cases regarding the warming of vitrified oocytes to reliably conclude whether oocyte cryopreservation is effective for patients with haematological malignancies. Further long-term follow-up study is required. WIDER IMPLICATIONS OF THE FINDINGS: Oocyte retrieval and oocyte cryopreservation were accessible for patients with haematological malignancies; however, the number of oocyte retrievals may have been limited due to the initiation of cancer treatments. Acceptable embryonic and pregnancy outcomes could be achieved following oocyte warming; therefore, our results suggest that oocyte cryopreservation can be considered an option for fertility preservation in patients with haematological malignancies. STUDY FUNDING/COMPETING INTERESTS: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.

2.
J Small Anim Pract ; 61(1): 64-67, 2020 Jan.
Article in English | MEDLINE | ID: mdl-29708273

ABSTRACT

An entire, female, mixed-breed cat of unknown age was presented with a 6-week history of lethargy, anorexia and vomiting. There was an increase in the number of white blood cells in the blood, including neutrophils and eosinophils; moderate anaemia; ascites; and possible mesenteric peritonitis. Exploratory laparotomy revealed firm, multifocal small nodules in the mesentery. As the nodules were surgically unresectable, they were biopsied. Histologically, the nodules were composed of thin trabeculae of dense collagen fibres mixed with plump fibroblasts and numerous eosinophils, consistent with feline gastrointestinal eosinophilic sclerosing fibroplasia. Bacteria were not detected on histological examination of the nodules and cytology of the ascites. Remission of disease occurred following treatment with prednisolone and ciclosporin A for 22 days and antibiotics for 40 days. After remission, ciclosporin A was administered for 236 days and then discontinued. Eosinophilia also resolved after treatment with ciclosporin A. The cat is still alive and in good condition on day 689. This report describes what may be an atypical case of feline gastrointestinal eosinophilic sclerosing fibroplasia, lacking involvement of the gastrointestinal tract, and was apparently cured by treatment that involved ciclosporin A.


Subject(s)
Eosinophilia/veterinary , Gastrointestinal Diseases/veterinary , Animals , Biopsy/veterinary , Cat Diseases , Cats , Female , Mesentery
3.
Sci Rep ; 9(1): 15041, 2019 10 21.
Article in English | MEDLINE | ID: mdl-31636327

ABSTRACT

Ovulation consists of a follicle's rupture and subsequent oocyte extrusion, although there is a paucity of evidence regarding whether every follicle's rupture is associated with extrusion of its oocyte. We examined this issue in a large-scale window-of-opportunity study by attempting aspiration of single dominant follicles that were found to have ruptured before a scheduled oocyte retrieval during in vitro fertilisation and embryo transfer treatment of infertile women. We were able to aspirate 587 of 1,071 ultrasonographically confirmed post-rupture dominant follicles from 1,071 women (i.e. one dominant follicle per woman) and retrieved 225 oocytes (oocyte recovery ratio: 43.4% of aspirated follicles), which yielded 28 live births (live birth ratio: 11.0% of retrieved oocytes). Interestingly, the live birth ratio for post-rupture dominant follicles was not statistically different from that achieved using regular pre-rupture aspiration of dominant follicles (1,085/8,977, 12.1%). These findings suggest that oocyte extrusion frequently does not occur after follicle rupture in infertile women undergoing in vitro fertilisation treatment, although the oocyte retained in the follicle can remain competent for use during that treatment.


Subject(s)
Infertility, Female/pathology , Oocytes/pathology , Ovarian Follicle/pathology , Rupture/pathology , Adult , Cell Differentiation , Cumulus Cells/pathology , Female , Humans , Oocyte Retrieval
4.
Chem Commun (Camb) ; 52(58): 9067-70, 2016 Jul 12.
Article in English | MEDLINE | ID: mdl-26890187

ABSTRACT

Incorporation of early druggability assessment in the drug discovery process provides a means to prioritize target proteins for high-throughput screening. We present chemical fragment arrays as a method that is capable of determining the druggability of a given target with low protein and compound consumption, enabling rapid decision making during early phases of drug discovery.

5.
Oncogene ; 34(1): 73-83, 2015 Jan 02.
Article in English | MEDLINE | ID: mdl-24336325

ABSTRACT

Malignant mesothelioma (MM) is one of the most aggressive neoplasms usually associated with asbestos exposure and is highly refractory to current therapeutic modalities. MMs show frequent activation of a transcriptional coactivator Yes-associated protein (YAP), which is attributed to the neurofibromatosis type 2 (NF2)-Hippo pathway dysfunction, leading to deregulated cell proliferation and acquisition of a malignant phenotype. However, the whole mechanism of disordered YAP activation in MMs has not yet been well clarified. In the present study, we investigated various components of the NF2-Hippo pathway, and eventually found that MM cells frequently showed downregulation of LIM-domain protein AJUBA, a binding partner of large tumor suppressor type 2 (LATS2), which is one of the last-step kinases of the NF2-Hippo pathway. Although loss of AJUBA expression was independent of the alteration status of other Hippo pathway components, MM cell lines with AJUBA inactivation showed a more dephosphorylated (activated) level of YAP. Immunohistochemical analysis showed frequent downregulation of AJUBA in primary MMs, which was associated with YAP constitutive activation. We found that AJUBA transduction into MM cells significantly suppressed promoter activities of YAP-target genes, and the suppression of YAP activity by AJUBA was remarkably canceled by knockdown of LATS2. In connection with these results, transduction of AJUBA-expressing lentivirus significantly inhibited the proliferation and anchorage-independent growth of the MM cells that harbored ordinary LATS family expression. Taken together, our findings indicate that AJUBA negatively regulates YAP activity through the LATS family, and inactivation of AJUBA is a novel key mechanism in MM cell proliferation.


Subject(s)
Gene Expression Regulation, Neoplastic , LIM Domain Proteins/metabolism , Lung Neoplasms/metabolism , Mesothelioma/metabolism , Protein Serine-Threonine Kinases/metabolism , Adaptor Proteins, Signal Transducing/metabolism , Cell Adhesion , Cell Line, Tumor , Cell Proliferation , Cytoplasm/metabolism , Hippo Signaling Pathway , Humans , Immunohistochemistry , Lentivirus/genetics , Mesothelioma, Malignant , Neurofibromin 2/metabolism , Phenotype , Phosphoproteins/metabolism , Phosphorylation , RNA, Small Interfering/metabolism , Signal Transduction , Transcription Factors , YAP-Signaling Proteins
6.
Lett Appl Microbiol ; 59(4): 377-83, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24863673

ABSTRACT

Acivicin is an inhibitor of γ-glutamyl transpeptidase and glutamine amidotransferase. When grown on a synthetic minimal agar medium, acivicin strongly inhibited the growth of Magnaporthe oryzae and Alternaria brassicicola, and to a lesser extent, Botrytis cinerea. However, only partial or marginal growth inhibition was observed with regard to Fusarium sporotrichioides and Fusarium graminearum. The growth retardation caused by acivicin was significantly alleviated by cultivating the fungus on a nutrient-rich medium. The inhibition of M. oryzae growth caused by 1 µmol l(-1) of acivicin on minimal agar medium was subdued by the addition of specific single amino acids, including His, a branched-chain amino acid (Leu, Ile or Val), an aromatic amino acid (Trp, Tyr or Phe), Met or Gln, at a concentration of 0·4 mmol l(-1). Trichothecene production by F. graminearum in trichothecene-inducing liquid medium was reduced significantly in the presence of acivicin despite its inability to inhibit growth in the trichothecene-inducing liquid medium. Foliar application of conidia in the presence of acivicin reduced the severity of rice blast disease caused by M. oryzae. These results suggest the usefulness of this modified amino acid natural product to mitigate agricultural problems caused by some phytopathogenic fungi. Significance and impact of the study: Fusarium head blight or scab disease and rice blast, caused by Fusarium graminearum and Magnaporthe oryzae, respectively, are major diseases of cereal crops that cause a significant loss of yield and deterioration in the quality of the grain. The present study investigated the effects of acivicin, a glutamine amino acid analog, on the physiology of various phytopathogenic fungi. Application of acivicin to a fungal culture and conidial suspension reduced mycotoxin production by the wheat scab fungus and the severity of rice blast, respectively. These results suggest the possibility that acivicin may serve as a lead compound to develop agricultural chemicals for the control of some plant diseases.


Subject(s)
Fusarium/drug effects , Isoxazoles/pharmacology , Magnaporthe/drug effects , Mycotoxins/metabolism , Plant Diseases/microbiology , Fusarium/metabolism , Fusarium/pathogenicity , Magnaporthe/metabolism , Magnaporthe/pathogenicity , Oryza/microbiology , Spores, Fungal , Triticum/microbiology , Virulence
7.
Oncogene ; 33(33): 4242-52, 2014 Aug 14.
Article in English | MEDLINE | ID: mdl-24077290

ABSTRACT

The mitotic spindle is assembled by the coordinated action of centrosomes and kinetochore microtubules. An evolutionally conserved protein family, transforming acidic coiled-coil (TACC), has been shown to be involved in this process. In humans, TACC3 is aberrantly expressed in a variety of human cancers, but its biological significance remains to be elucidated. Here, using a novel compound targeting TACC3, spindlactone (SPL), we show that the perturbation of TACC3 selectively inhibited the nucleation of centrosome microtubules in ovarian cancer cells. In contrast to centrosome microtubules, the kinetochore microtubules were robustly assembled, forming ectopic spindle poles that resulted in multipolar spindles. Interestingly, the extensive inhibition of TACC3 partially suppressed the nucleation of kinetochore microtubules. These dose-dependent effects of SPL were consistent with the results observed by the depletion of TACC3 and its binding partner, colonic and hepatic tumor overexpressed gene protein (TOGp). Although these proteins both have roles in the assembly of centrosome and kinetochore microtubules, their contributions were spatiotemporally different. Notably, SPL did not affect spindle assembly in normal cells. Furthermore, the oral administration of SPL significantly suppressed tumor growth in vivo. The unique mechanism of action of SPL not only enables it to be used as a tool to dissect the molecular basis of spindle assembly but also to provide a rationale for the use of TACC3 as a molecular target for cancer treatment. This rationale offers an opportunity to develop new strategies for cancer chemotherapy that overcome the limitations of microtubule toxins and expand their scope and clinical efficacy.


Subject(s)
Antineoplastic Agents/pharmacology , Coumarins/pharmacology , Microtubule-Associated Proteins/metabolism , Spindle Apparatus/metabolism , Animals , Cell Line, Tumor , Cell Proliferation/drug effects , Centrosome/metabolism , Heterografts , Humans , Mice , Mice, Inbred NOD , Mice, SCID , Microtubule-Associated Proteins/antagonists & inhibitors , Microtubules/metabolism , Time-Lapse Imaging , Tumor Burden/drug effects
8.
J Dent Res ; 91(8): 771-6, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22674934

ABSTRACT

In osteoprotegerin-deficient (OPG-/-) mice, osteoclast activity causes bone resorption to outpace bone formation, leading to the development of severe osteoporosis. Such mice are therefore useful for investigating the alveolar bone of patients with osteoporosis. Reveromycin A (RM-A) was recently identified as the unique agent acting on osteoclast activation. This study aimed to analyze the effect of RM-A on the orthodontic treatment of OPG-/- mice (a model of osteoporosis patients with high levels of bone turnover). We examined alveolar bone remodeling in OPG-/- and wild-type (WT) mice during continuous tooth movement. The orthodontic force was induced by means of a Ni-Ti closed-coil spring to move the maxillary first molar for 14 days. RM-A sodium salt (1 mg/kg) was administered intraperitoneally twice daily. In OPG-/- mice, the tooth movement distance was longer, alveolar bone resorption was enhanced, the osteoclast count was greater, and serum alkaline phosphatase and tartrate-resistant acid phosphatase levels were higher relative to those in WT mice. However, the administration of RM-A in OPG-/- mice reduced these parameters. We conclude that RM-A normalizes bone metabolism and loss of alveolar bone during continuous tooth movement in OPG-/- mice.


Subject(s)
Alveolar Process/drug effects , Bone Density Conservation Agents/pharmacology , Bone Remodeling/drug effects , Pyrans/pharmacology , Spiro Compounds/pharmacology , Tooth Movement Techniques , Acid Phosphatase/blood , Alkaline Phosphatase/blood , Alveolar Process/pathology , Animals , Biomarkers/blood , Bone Density Conservation Agents/administration & dosage , Bone Resorption/pathology , Bone Resorption/physiopathology , Cell Count , Dental Alloys/chemistry , Disease Models, Animal , Injections, Intraperitoneal , Isoenzymes/blood , Male , Maxilla/drug effects , Maxilla/pathology , Mice , Mice, Inbred C57BL , Mice, Inbred Strains , Mice, Knockout , Mutation/genetics , Nickel/chemistry , Orthodontic Wires , Osteitis Deformans/genetics , Osteitis Deformans/physiopathology , Osteoclasts/drug effects , Osteoclasts/pathology , Osteoporosis/genetics , Osteoporosis/physiopathology , Osteoprotegerin/genetics , Pyrans/administration & dosage , Spiro Compounds/administration & dosage , Tartrate-Resistant Acid Phosphatase , Titanium/chemistry , X-Ray Microtomography
9.
Oncogene ; 31(49): 5117-22, 2012 Dec 06.
Article in English | MEDLINE | ID: mdl-22286761

ABSTRACT

Malignant mesothelioma (MM) shows frequent inactivation of the neurofibromatosis type 2 (NF2) -tumor-suppressor gene. Recent studies have documented that the Hippo signaling pathway, a downstream cascade of Merlin (a product of NF2), has a key role in organ size control and carcinogenesis by regulating cell proliferation and apoptosis. We previously reported that MMs show overexpression of Yes-associated protein (YAP) transcriptional coactivator, the main downstream effector of the Hippo signaling pathway, which results from the inactivation of NF2, LATS2 and/or SAV1 genes (the latter two encoding core components of the mammalian Hippo pathway) or amplification of YAP itself. However, the detailed roles of YAP remain unclear, especially the target genes of YAP that enhance MM cell growth and survival. Here, we demonstrated that YAP-knockdown inhibited cell motility, invasion and anchorage-independent growth as well as cell proliferation of MM cells in vitro. We analyzed genes commonly regulated by YAP in three MM cell lines with constitutive YAP-activation, and found that the major subsets of YAP-upregulating genes encode cell cycle regulators. Among them, YAP directly induced the transcription of CCND1 and FOXM1, in cooperation with TEAD transcription factor. We also found that knockdown of CCND1 and FOXM1 suppressed MM cell proliferation, although the inhibitory effects were less evident than those of YAP knockdown. These results indicate that constitutive YAP activation in MM cells promotes cell cycle progression giving more aggressive phenotypes to MM cells.


Subject(s)
Cell Cycle/genetics , Mesothelioma/genetics , Mesothelioma/pathology , Nuclear Proteins/metabolism , Transcription Factors/metabolism , Cell Cycle Proteins , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation , Cyclin D1/genetics , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Forkhead Box Protein M1 , Forkhead Transcription Factors/genetics , Gene Expression Regulation, Neoplastic , Gene Knockdown Techniques , Humans , Nuclear Proteins/genetics , TEA Domain Transcription Factors , Transcription Factors/genetics , Transcriptome , Up-Regulation
10.
J Perinatol ; 31(4): 269-73, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21052047

ABSTRACT

OBJECTIVE: Prognostic prediction in prenatally diagnosed congenital diaphragmatic hernia (CDH) is needed. The aim of the study was to evaluate magnetic resonance imaging (MRI) signal intensity of the fetal lung as a predictor of prognosis in CDH. STUDY DESIGN: The subjects consisted of 12 fetuses with prenatally diagnosed CDH, who were treated soon after the birth in our institution. They all underwent MRI at 29 to 37 weeks of gestation. The ratio of the lung signal intensity to the spinal fluid signal intensity (L/SF) was calculated using region-of-interest analysis of T2-weighted images. The relationship between L/SF and clinical data was then examined. RESULT: L/SF were significantly larger in survivors compared with deaths (0.815 vs 0.614, P<0.05). In survivors, L/SF significantly correlated with duration of tracheal intubation (rs=-0.938, P<0.01). CONCLUSION: L/SF is a unique factor to predict the survival prognosis and likely to quantify the degree of pulmonary hypoplasia in CDH.


Subject(s)
Fetus/abnormalities , Magnetic Resonance Imaging/methods , Cerebrospinal Fluid , Diaphragm , Female , Hernia, Diaphragmatic/diagnosis , Hernia, Diaphragmatic/mortality , Hernia, Diaphragmatic/physiopathology , Hernia, Diaphragmatic/surgery , Hernias, Diaphragmatic, Congenital , Humans , Infant, Newborn , Lung , Perioperative Care , Pregnancy , Prenatal Diagnosis , Prognosis , Signal Processing, Computer-Assisted , Survival Analysis , Thoracic Surgical Procedures , Treatment Outcome
11.
Cell Death Differ ; 17(7): 1211-20, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20139893

ABSTRACT

Abl tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib are ineffective against Bcr-Abl(+) leukemic stem cells. Thus, the identification of novel agents that are effective in eradicating quiescent Bcr-Abl(+) stem cells is needed to cure leukemias caused by Bcr-Abl(+) cells. Human Bcr-Abl(+) cells engrafted in the bone marrow of immunodeficient mice survive under severe hypoxia. We generated two hypoxia-adapted (HA)-Bcr-Abl(+) sublines by selection in long-term hypoxic cultures (1.0% O(2)). Interestingly, HA-Bcr-Abl(+) cells exhibited stem cell-like characteristics, including more cells in a dormant, increase of side population fraction, higher beta-catenin expression, resistance to Abl TKIs, and a higher transplantation efficiency. Compared with the respective parental cells, HA-Bcr-Abl(+) cells had higher levels of protein and higher enzyme activity of glyoxalase-I (Glo-I), an enzyme that detoxifies methylglyoxal, a cytotoxic by-product of glycolysis. In contrast to Abl TKIs, Glo-I inhibitors were much more effective in killing HA-Bcr-Abl(+) cells both in vitro and in vivo. These findings indicate that Glo-I is a novel molecular target for treatment of Bcr-Abl(+) leukemias, and, in particular, Abl TKI-resistant quiescent Bcr-Abl(+) leukemic cells that have acquired stem-like characteristics in the process of adapting to a hypoxic environment.


Subject(s)
Lactoylglutathione Lyase/antagonists & inhibitors , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Neoplastic Stem Cells/drug effects , Animals , Benzamides , Cell Hypoxia , Cell Line, Tumor , Dasatinib , Humans , Imatinib Mesylate , Lactoylglutathione Lyase/metabolism , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology , Mice , Piperazines/pharmacology , Protein Kinase Inhibitors/pharmacology , Pyrimidines/pharmacology , Thiazoles/pharmacology , Transplantation, Heterologous , beta Catenin/metabolism
12.
Oncogene ; 28(38): 3371-9, 2009 Sep 24.
Article in English | MEDLINE | ID: mdl-19597473

ABSTRACT

Small-cell lung cancer (SCLC) is a highly aggressive disease that exhibits rapid growth and genetic instability. We found earlier frequent overexpression of the miR-17-92 microRNA cluster, and showed that SCLC cells were addicted to continued expressions of miR-17-5p and miR-20a, major components of this microRNA cluster. In this study, we identified the frequent presence of constitutively phosphorylated H2AX (gamma-H2AX), which reflects continuing DNA damage, preferentially in SCLC. Knockdown of RB induced gamma-H2AX foci formation in non-small cell lung cancer (NSCLC) cells with wild-type RB, in association with growth inhibition and reactive oxygen species (ROS) generation, which was canceled by overexpression of miR-17-92. Conversely, induction of gamma-H2AX was observed in a miR-17-92-overexpressing SCLC cell line with miR-20a antisense oligonucleotides. These findings suggest that miR-17-92 overexpression may serve as a fine-tuning influence to counterbalance the generation of DNA damage in RB-inactivated SCLC cells, thus reducing excessive DNA damage to a tolerable level and consequently leading to genetic instability. Therefore, miR-17-92 may be an excellent therapeutic target candidate to elicit excessive DNA damage in combination with DNA-damaging chemotherapeutics.


Subject(s)
Carcinoma, Small Cell/metabolism , DNA Damage , Lung Neoplasms/metabolism , MicroRNAs/physiology , Reactive Oxygen Species/metabolism , Retinoblastoma Protein/physiology , Carcinoma, Small Cell/pathology , Cell Line, Tumor , Cyclin E/physiology , Histones/genetics , Histones/metabolism , Humans , Lung Neoplasms/pathology , Phosphorylation , Protein Phosphatase 2/genetics
13.
Oncogene ; 28(1): 107-16, 2009 Jan 08.
Article in English | MEDLINE | ID: mdl-18820703

ABSTRACT

Bcl-x(L), an anti-apoptotic Bcl-2 family member protein, contributes to the resistance against chemotherapies such as tubulin-binder treatment in many human tumors. Although Bcl-x(L) is phosphorylated after tubulin-binder treatment, the role of the phosphorylation and its responsible kinase(s) are poorly understood. Here, we identified Plk1 (polo-like kinase 1) as a Bcl-x(L) kinase. Same location of Bcl-x(L) and Plk1 was revealed by immunocytochemical analyses at M-phase in situ. Plk1 phosphorylates Bcl-x(L) in vitro, and we identified Plk1 phosphorylation sites in Bcl-x(L). When all of these phosphorylation sites were substituted to alanines, the anti-apoptotic activity of the Bcl-x(L) mutant against the apoptosis induced by pironetin, but not against ultraviolet-induced apoptosis, was increased. These observations suggest that Plk1 is a regulator of Bcl-x(L) phosphorylation and controls the anti-apoptotic activity of Bcl-x(L) during pironetin-induced apoptosis.


Subject(s)
Apoptosis , Cell Cycle Proteins/metabolism , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , bcl-X Protein/metabolism , Alanine/genetics , Alanine/metabolism , Cell Line, Tumor , Humans , Mutation , Phosphorylation , Pyrones/pharmacology , Serine/metabolism , bcl-X Protein/genetics , Polo-Like Kinase 1
14.
Clin Nephrol ; 69(4): 310-2, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18397709

ABSTRACT

Intact PTH measures not only 1-84 PTH, but also other fragments such as 7-84 PTH. Lately, a measurement of 1-84 PTH has been available as whole PTH assay and the ratio of whole PTH/intact PTH is considered to be between 0.5 and 0.7 in patients on hemodialysis. Therefore, intact PTH should be higher than whole PTH. We present a 57-year-old male with chronic renal failure on hemodialysis whose whole PTH was higher than intact PTH (the reversed ratio of whole PTH/intact PTH). He showed one enlarged parathyroid gland by an ultrasonic test, CT examination and RI subtraction study. After this gland was removed by surgery, the ratio of whole PTH/intact PTH normalized. The size of the resected gland was 22 x 15 x 11 mm. The histologic examination revealed adenoma. This indicates that, if patients with chronic renal failure showed the reversed ratio of whole PTH/intact PTH, the possibility that they could have primary hyperparathyroidism in addition to secondary hyperparathyroidism should be considered.


Subject(s)
Hyperparathyroidism, Primary/blood , Parathyroid Hormone/blood , Renal Dialysis , Adenoma/diagnosis , Humans , Hyperparathyroidism, Primary/etiology , Hyperparathyroidism, Primary/surgery , Kidney Failure, Chronic/therapy , Male , Middle Aged , Parathyroid Glands/surgery , Parathyroid Neoplasms/diagnosis , Parathyroidectomy
15.
Br J Neurosurg ; 21(6): 599-602, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18071988

ABSTRACT

Two patients with glossopharyngeal neuralgia associated with cardiac syncope were treated with temporary cardiac pacemakers for cardiac syncope and then microvascular decompression. The offending arteries were the posterior inferior cerebellar artery in one patient and the anterior inferior cerebellar artery in the other. The offending arteries were attached to the glossopharyngeal nerve and the vagal nerve at the root entry zones. After surgery, the patients were free from neuralgia and cardiac syncope did not occur after the pacemakers were extracted. Implantation of a temporary cardiac pacemaker in the perioperative period ensures safe microvascular decompression.


Subject(s)
Cerebral Arteries/surgery , Glossopharyngeal Nerve Diseases/surgery , Nerve Compression Syndromes/surgery , Neuralgia/surgery , Syncope/surgery , Vagus Nerve Diseases/surgery , Aged, 80 and over , Cardiac Pacing, Artificial/methods , Decompression, Surgical/methods , Electrocardiography/methods , Female , Glossopharyngeal Nerve Diseases/complications , Humans , Microsurgery/methods , Middle Aged , Nerve Compression Syndromes/complications , Neuralgia/complications , Neurosurgical Procedures/methods , Pacemaker, Artificial , Syncope/complications , Vagus Nerve Diseases/complications
16.
Minim Invasive Neurosurg ; 50(4): 195-201, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17948177

ABSTRACT

OBJECT: The supraorbital keyhole approach via an eyebrow skin incision provides a method for the minimally invasive clipping of aneurysms located in the circle of Willis, but has disadvantages for aneurysms located in the lateral Sylvian fissure. The pterional keyhole minicraniotomy via an outer canthal skin incision is proposed for the clipping of unruptured aneurysms of the middle cerebral artery (MCA). METHODS: The procedure consists of a 35-mm outer canthal skin incision, partial temporal muscle dissection restricted in the pterion, a 20-25-mm keyhole minicraniotomy, and a 15-20-mm dural incision to expose the lateral Sylvian fissure. Twenty keyhole clipping procedures were performed in 20 patients with unruptured MCA aneurysms. RESULTS: Only one patient showed a temporary mild hemiparesis (reversible ischemic neurological deficit) due to lacunar infarction. No shaving of scalp hair, drain placement, or anticonvulsant drug administration were required. Most patients were discharged on the 2nd or 3rd postoperative day. One patient showed a weakness of the frontalis muscle, but this complication was eliminated by the definition of a safety zone to avoid damage to the frontal branch of the facial nerve. CONCLUSIONS: The pterional keyhole approach via outer an canthal skin incision is another treatment option for relatively small, unruptured MCA aneurysms.


Subject(s)
Craniotomy/methods , Eyelids/surgery , Intracranial Aneurysm/surgery , Minimally Invasive Surgical Procedures/methods , Skull/surgery , Vascular Surgical Procedures/methods , Aged , Cerebral Angiography , Cicatrix/prevention & control , Dura Mater/anatomy & histology , Dura Mater/surgery , Eyelids/anatomy & histology , Facial Nerve/anatomy & histology , Facial Nerve/surgery , Facial Nerve Injuries/prevention & control , Female , Humans , Intracranial Aneurysm/pathology , Male , Middle Aged , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Preoperative Care , Skull/anatomy & histology , Surgical Instruments , Temporal Arteries/anatomy & histology , Temporal Arteries/surgery , Temporal Muscle/anatomy & histology , Temporal Muscle/surgery , Tomography, X-Ray Computed , Treatment Outcome
18.
Acta Paediatr ; 96(3): 363-7, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17407457

ABSTRACT

AIM: Normal variation in size at birth is a result of the interaction between fetal genetic factors and the maternal uterine environment. It is, however, unclear how genetic factors contribute to fetal growth. The insulin-like growth factor (IGF) system regulates uterine, placental and fetal development, thereby partially controlling the rate of fetal growth. The aim of this study was to investigate the associations between the neonatal birth weight and the genotypes of polymorphic loci in the IGF2 and IGF2 receptor (IGF2R) genes. METHODS: We determined the genotypes of two polymorphic loci in the IGF2 gene and four loci in the IGF2R gene in 884 pairs of normal Japanese mothers and their neonates, and compared the genotypes with the birth weight converted into standard deviation scores (SDSs) according to sex, parity and gestational weeks at delivery. RESULTS: There was a significant difference in birth weight SDSs among the three neonatal +3123/ApaI genotypes of the IGF2 gene; AA, AG and GG. There was also a significant difference in birth weight among the three neonatal c.901C > G genotypes of the IGF2R gene; CC, CG and GG. CONCLUSION: These findings indicate that both IGF2 and IGF2R gene variants are associated with fetal growth.


Subject(s)
Fetal Development/genetics , Fetus/physiology , Polymorphism, Single Nucleotide/physiology , Proteins/genetics , Receptor, IGF Type 2/genetics , Adult , Asian People/genetics , Female , Genotype , Humans , Insulin-Like Growth Factor II , Pregnancy
19.
Oncogene ; 26(41): 6099-105, 2007 Sep 06.
Article in English | MEDLINE | ID: mdl-17384677

ABSTRACT

Amplification and overexpression of the miR-17-92 microRNAs (miRNA) cluster at 13q31.3 has recently reported, with pointers to functional involvement in the development of B-cell lymphomas and lung cancers. In the present study, we show that inhibition of miR-17-5p and miR-20a with antisense oligonucleotides (ONs) can induce apoptosis selectively in lung cancer cells overexpressing miR-17-92, suggesting the possibility of 'OncomiR addiction' to expression of these miRNAs in a subset of lung cancers. In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth. During the course of this study, we also found that enforced expression of a genomic region, termed C2, residing 3' to miR-17-92 in the intron 3 of C13orf25 led to marked growth inhibition in association with double stranded RNA-dependent protein kinase activation. Finally, this study also revealed that the vast majority of C13orf25 transcripts are detected as Drosha-processed cleavage products on Northern blot analysis and that a novel polyadenylation site is present 3' to the miR-17-92 cluster and 5' to the C2 region. Taken together, the present findings contribute towards better understanding of the oncogenic roles of miR-17-92, which might ultimately lead to the future translation into clinical applications.


Subject(s)
Apoptosis/drug effects , Oligonucleotides, Antisense/pharmacology , Cell Division/drug effects , Cell Line, Tumor , Chromosomes, Human, Pair 13 , Humans , In Situ Nick-End Labeling , Lung Neoplasms/pathology , MicroRNAs/genetics , Open Reading Frames , Transcription, Genetic
20.
Oncogene ; 26(27): 4025-31, 2007 Jun 07.
Article in English | MEDLINE | ID: mdl-17213806

ABSTRACT

We previously established a highly metastatic subline, LNM35, from the NCI-H460 lung cancer cell line, and demonstrated upregulation of a novel gene, CLCP1 (CUB, LCCL-homology, coagulation factor V/VIII homology domains protein), in LNM35 and lung cancer specimens. In this study, we focused on the potential roles of that gene in cancer metastasis. First, we established stable LNM35 RNAi clones, in which CLCP1 expression was suppressed by RNAi, and found that their motility was significantly reduced, although growth rates were not changed. Next, in vitro selection of a phage display library demonstrated that a phage clone displaying a peptide similar to a sequence within the Sema domain of semaphorin 4B (SEMA4B) interacted with LNM35. Immunoprecipitation experiments confirmed interaction of CLCP1 with SEMA4B, regulation of CLCP1 protein by ubiquitination and proteasome degradation enhanced in the presence of SEMA4B. These results are the first to indicate that CLCP1 plays a role in cell motility, whereas they also showed that at least one of its ligands is SEMA4B and that their interaction mediates proteasome degradation by CLCP1. Although the physiological role of the interaction between CLCP1 and SEMA4B remains to be investigated, this novel gene may become a target of therapy to inhibit metastasis of lung cancers.


Subject(s)
Cell Movement/physiology , Membrane Proteins/physiology , Semaphorins/metabolism , Amino Acid Sequence , Cell Line , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation , Cysteine Proteinase Inhibitors/pharmacology , Humans , Immunoblotting , Immunoprecipitation , Leupeptins/pharmacology , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Membrane Proteins/genetics , Membrane Proteins/metabolism , Oligopeptides/genetics , Oligopeptides/metabolism , Peptide Library , Proteasome Endopeptidase Complex/metabolism , Proteasome Inhibitors , Protein Binding/drug effects , RNA Interference , Semaphorins/genetics , Transfection , Tunicamycin/pharmacology , Ubiquitin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL